LOS ANGELES, Dec. 5, 2011 (GLOBE NEWSWIRE) -- CompuMed, Inc. (Pink Sheets:CMPD) (www.compumed.com), a telemedicine and medical informatics company, announced today that W. Scott Rombach, CEO of Rombach Capital, has been appointed to the Board of Directors.
Mr. Rombach has extensive experience as a sales executive at PeopleSoft, Inc. and at Armstrong Laing Group. Mr. Rombach brings expertise to the Board in sales strategy, as well as growth and execution within the technology industry.
"Scott's global executive sales background and deep understanding of the processes required in large complex markets and deal flow should serve CompuMed well at a time when we are expanding our sales and marketing channels. We are delighted to have him on board," said Maurizio Vecchione, CompuMed's President and CEO.
About CompuMed
CompuMed, Inc. develops and markets products and services that combine advanced imaging with medical informatics. Its focus is on analysis and remote monitoring for patients with cardiovascular and musculoskeletal diseases. The company has specialized expertise and intellectual property in tele-monitoring imaging and analysis designed to improve healthcare provider workflow and patient care while reducing costs. CompuMed is headquartered in Los Angeles and distributes its products worldwide both directly and through OEM partners. Visit CompuMed at www.compumed.net and follow at Twitter: @compumed.
Forward Looking Statement
Statements contained in this press release that are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth, results of contracts and other financial results, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including statements concerning the Company's plans, objectives, expectations and intentions are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are subject to uncertainties and risks including, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks identified in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-KSB and Quarterly Reports on Form 10-QSB. All such forward-looking statements are expressly qualified by these cautionary statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect events, conditions or circumstances on which any such statement is based after the date hereof, except as required by law.